Latest news with #MDx
Korea Herald
01-07-2025
- Business
- Korea Herald
Seegene Launches STAgora™, a New Platform for Infectious Disease Analytics
SEOUL, South Korea, July 1, 2025 /PRNewswire/ -- Seegene Inc., a global leader in molecular diagnostics (MDx) solutions, announced today the launch of STAgora™, a next-generation platform for infectious disease analytics. Designed as a real-time infectious disease intelligence system, the platform combines diagnostic data with advanced statistical modeling and aims to redefine how the world detects, tracks, and responds to outbreaks. STAgora™ provides real-time global visualization of infectious disease trends at the municipal, national, and continental levels, based on actual diagnostic test results. The platform delivers healthcare professionals immediate, structured diagnostic reports and statistical analyses in clear, actionable formats. These are supported by customizable dashboards and real-time alert functions. In addition to tracking individual cases, STAgora™ enables users to monitor outbreaks across selected regions, both local and international. This capability provides real-time visibility into disease spread, enhancing situational awareness and supporting timely, data-driven public health responses. By equipping national and global health authorities with real-time epidemiological insight, the platform is expected to strengthen decision-making and support the development of effective response strategies to mitigate large-scale infectious disease outbreaks. With more than 40 built-in statistical tools, STAgora™ enables early detection of abnormal pathogen patterns and supports predictive modeling for seasonal trends and emerging outbreaks. These tools include modules for tracking individual infections, analyzing symptom-based co-infections and calculating real-time infection rate trends. Together, they help transform static data into forward-looking intelligence that guides proactive interventions. Unlike traditional outbreak monitoring systems that rely on retrospective data, STAgora™ performs real-time analysis of PCR-derived diagnostics. This allows for immediate visibility into pathogen spread and, through AI-based algorithms, the forecasting of potential future outbreaks. "The key differentiator of STAgora™ is its unique architecture, which aggregates real-time diagnostic data from around the world into a unified analysis platform," said Young-Seag Baeg, head of strategic planning at Seegene. When paired with Seegene's proprietary syndromic quantitative PCR technology, STAgora™ offers expanded visibility into both single-pathogen infections and simultaneous multi-pathogen co-infections. This comprehensive diagnostic insight empowers clinicians to make faster, more informed decisions at the point of care. "During the COVID-19 pandemic, we saw firsthand how crucial accurate and timely interpretation of diagnostic data was in shaping public health policies and clinical outcomes," said Daniel Shin, executive vice president and chief global sales and marketing officer at Seegene. "Now, as we confront increasingly complex threats such as antimicrobial resistance, viral mutations and co-infections, the ability to deliver actionable insights from diagnostic data is becoming a cornerstone of clinical innovation and a vital pillar of global health security." Seegene will officially debut STAgora™ at the 2025 Association for Diagnostics & Laboratory Medicine (ADLM) annual meeting, taking place July 27 to 31 in Chicago, USA. The event will highlight key capabilities of the platform, including its integration with CURECA™, Seegene's fully automated, unmanned PCR system. ADLM 2025 will also serve as a launchpad for Seegene to explore global collaboration and partnerships with healthcare leaders and clients. With the launch of STAgora™, Seegene aims to lay the foundation for a smarter, faster and more connected global health defense system. By combining real-time molecular diagnostics, AI-driven analytics and global data integration, STAgora™ represents a strategic step toward building an intelligent public health infrastructure capable of responding proactively to emerging threats. The company envisions the platform as a core pillar of the global infectious disease response framework, marking a new step toward enhanced diagnostic insight and preparedness. About Seegene Seegene has more than 20 years of dedicated experience in R&D, manufacturing, and business related to syndromic real-time PCR technologies. This expertise was particularly highlighted during the COVID-19 pandemic when Seegene provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene's syndromic real-time PCR technology is the ability to simultaneously test for 14 pathogens that cause similar signs and symptoms in a single tube with quantitative information. CURECA™(Continuous, Unlimited, Random-access, Expandable, and Customizable Automation) is a fully automated and modular PCR system that eliminates manual processes and enables continuous, real-time testing. It is a unified platform designed to operate continuously, 24 hours a day, with no human intervention. The very core feature is CPS which is the first part of CURECA™, the world's first automated pre-treatment system capable of handling a full spectrum of specimen types, including blood, stool, sputum, and urine. Designed to support both centralized and decentralized labs, CURECA offers scalable automation and flexible adoption—making it especially valuable in settings with limited space or personnel.
Cision Canada
01-07-2025
- Business
- Cision Canada
Seegene Launches STAgora™, a New Platform for Infectious Disease Analytics
SEOUL, South Korea, July 1, 2025 /CNW/ -- Seegene Inc., a global leader in molecular diagnostics (MDx) solutions, announced today the launch of STAgora™, a next-generation platform for infectious disease analytics. Designed as a real-time infectious disease intelligence system, the platform combines diagnostic data with advanced statistical modeling and aims to redefine how the world detects, tracks, and responds to outbreaks. STAgora™ provides real-time global visualization of infectious disease trends at the municipal, national, and continental levels, based on actual diagnostic test results. The platform delivers healthcare professionals immediate, structured diagnostic reports and statistical analyses in clear, actionable formats. These are supported by customizable dashboards and real-time alert functions. In addition to tracking individual cases, STAgora™ enables users to monitor outbreaks across selected regions, both local and international. This capability provides real-time visibility into disease spread, enhancing situational awareness and supporting timely, data-driven public health responses. By equipping national and global health authorities with real-time epidemiological insight, the platform is expected to strengthen decision-making and support the development of effective response strategies to mitigate large-scale infectious disease outbreaks. With more than 40 built-in statistical tools, STAgora™ enables early detection of abnormal pathogen patterns and supports predictive modeling for seasonal trends and emerging outbreaks. These tools include modules for tracking individual infections, analyzing symptom-based co-infections and calculating real-time infection rate trends. Together, they help transform static data into forward-looking intelligence that guides proactive interventions. Unlike traditional outbreak monitoring systems that rely on retrospective data, STAgora™ performs real-time analysis of PCR-derived diagnostics. This allows for immediate visibility into pathogen spread and, through AI-based algorithms, the forecasting of potential future outbreaks. "The key differentiator of STAgora™ is its unique architecture, which aggregates real-time diagnostic data from around the world into a unified analysis platform," said Young-Seag Baeg, head of strategic planning at Seegene. When paired with Seegene's proprietary syndromic quantitative PCR technology, STAgora™ offers expanded visibility into both single-pathogen infections and simultaneous multi-pathogen co-infections. This comprehensive diagnostic insight empowers clinicians to make faster, more informed decisions at the point of care. "During the COVID-19 pandemic, we saw firsthand how crucial accurate and timely interpretation of diagnostic data was in shaping public health policies and clinical outcomes," said Daniel Shin, executive vice president and chief global sales and marketing officer at Seegene. "Now, as we confront increasingly complex threats such as antimicrobial resistance, viral mutations and co-infections, the ability to deliver actionable insights from diagnostic data is becoming a cornerstone of clinical innovation and a vital pillar of global health security." Seegene will officially debut STAgora™ at the 2025 Association for Diagnostics & Laboratory Medicine (ADLM) annual meeting, taking place July 27 to 31 in Chicago, USA. The event will highlight key capabilities of the platform, including its integration with CURECA™, Seegene's fully automated, unmanned PCR system. ADLM 2025 will also serve as a launchpad for Seegene to explore global collaboration and partnerships with healthcare leaders and clients. With the launch of STAgora™, Seegene aims to lay the foundation for a smarter, faster and more connected global health defense system. By combining real-time molecular diagnostics, AI-driven analytics and global data integration, STAgora™ represents a strategic step toward building an intelligent public health infrastructure capable of responding proactively to emerging threats. The company envisions the platform as a core pillar of the global infectious disease response framework, marking a new step toward enhanced diagnostic insight and preparedness. About Seegene Seegene has more than 20 years of dedicated experience in R&D, manufacturing, and business related to syndromic real-time PCR technologies. This expertise was particularly highlighted during the COVID-19 pandemic when Seegene provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene's syndromic real-time PCR technology is the ability to simultaneously test for 14 pathogens that cause similar signs and symptoms in a single tube with quantitative information. CURECA™(Continuous, Unlimited, Random-access, Expandable, and Customizable Automation) is a fully automated and modular PCR system that eliminates manual processes and enables continuous, real-time testing. It is a unified platform designed to operate continuously, 24 hours a day, with no human intervention. The very core feature is CPS which is the first part of CURECA™, the world's first automated pre-treatment system capable of handling a full spectrum of specimen types, including blood, stool, sputum, and urine. Designed to support both centralized and decentralized labs, CURECA offers scalable automation and flexible adoption—making it especially valuable in settings with limited space or personnel.
Korea Herald
03-05-2025
- Business
- Korea Herald
Seegene's CURECA(TM) Emerges as a Potential Game Changer in End-to-End PCR Automation
SEOUL, South Korea, May 2, 2025 /PRNewswire/ -- Seegene Inc., a global leader in molecular diagnostics (MDx) solutions, has attracted strong interest after the company presented a conceptual video of its CURECA TM at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) in Vienna, Austria. Industry professionals recognized CURECA TM as a promising advancement in automating the entire PCR diagnostic workflow — from primary sample handling to result analysis. In response to the interest received, Seegene provided additional opportunities to showcase the solution at the ESCMID Global 2025. More than 2,300 attendees — including dignitaries from Italy, Spain, Germany, France, and Canada — visited Seegene's booth to view the conceptual video introducing the CURECA TM. "It was evident that the Seegene booth attracted considerable attention at ESCMID," said one professional from academia. Experts Recognize CURECA TM as a Game Changer in Molecular Testing Automation The CURECA TM is designed to automate the entire PCR diagnostic process. It can handle various specimen types required in the pre-treatment stage in MDx – such as stool, urine, blood, and sputum—as well as perform the complete PCR testing workflow following sample loading. The following are select comments from industry professionals who previewed Seegene's CURECA TM at ESCMID Global 2025: "I hold high expectations for the fully automated PCR molecular diagnostics, as CURECA TM not only eliminates human error inherent in manual processes but also enables efficient testing without time or workforce constraints." "We often encounter specimen types that require careful and time-consuming manual pre-processing. A system that can automate this step could represent a true paradigm shift. This level of automation is transformative – a real game changer – and unlike any existing solution. I eagerly await its launch." "If paired with our in-house diagnostic tool kits, CURECA TM could offer a complete synergy. I hope CURECA TM will be accessible to small and mid-sized facilities." "I'm planning to attend ADLM 2025 in Chicago in July to see the actual device and explore potential collaborations." Customizable Pre-Treatment System Offers Versatility for Future Laboratory Automation The first component of CURECA TM is the Customizable Pre-treatment System (CPS). The CPS is designed to automate the loading of primary sample tubes and operate pre-treatment processing. "The CPS is a modular, automated system intended to streamline pre-treatment processing across diverse diagnostic fields including molecular diagnostics such as PCR, as well as clinical chemistry and immunology assays," said Young-Seag Baeg, Head of Strategy and Planning at Seegene. Numerous healthcare (or laboratory) professionals at ESCMID Global 2025 noted that the conceptual video of CURECA TM showcased the potential of fully automated diagnostic laboratories capable of managing complex workflows associated with pre-treatment. In particular, there was consensus among participants that the CPS, which automates specimen preprocessing, is positioned to bring a significant advancement in in vitro diagnostics as it addresses limitations associated with existing manual procedures that are dependent on trained laboratory professionals. "The turnaround time (TAT) is expected to improve with CURECA TM as the integrated software is capable of adjusting workflows based on reporting deadlines," said a director of a laboratory in Spain. "In particular, for sexually transmitted infections (STIs), the CPS will markedly enhance daily laboratory operations. The processing of specimens for STIs involves manual handling of multiple sample tubes, which contributes to operator fatigue. The adoption of the CPS has the potential to be transformational in streamlining routine operations." Modular and Configurable Solution Design for Tailored Diagnostics Following specimen preprocessing, molecular diagnostics typically involve nucleic acid extraction, PCR setup and amplification, and analysis of results. For specimens that do not need preprocessing, Seegene offers the Primary Sample Aliquot System (PAS) as an alternative to the CPS. PAS is designed to allow direct loading and dispensing of primary samples, helping to simplify the workflow. Seegene is pursuing the integration of PAS with a fully automated PCR process through a modular solution concept called CEFA (Customizable & Expandable Full Automation), intended to support diverse laboratory needs with greater flexibility. Seegene aims to leverage the modular architecture of CURECA TM to support a wide range of diagnostic applications. "CURECA TM can be deployed as a comprehensive system or as individual modules—CPS, PAS, and CEFA—configured independently or in combination to accommodate diverse operational needs," said Baeg. Optimizing Lab Workflows Through Space-Saving Design Another key advantage of the CURECA TM 's modular architecture is that it is designed to adapt to different laboratory spaces and layouts. Its flexible design is intended to allow labs to configure the system according to their specific needs, which Seegene sees as essential for enhancing operational efficiency. Laboratory professionals at ESCMID 2025 shared the following perspectives: "The ability to configure a system to meet specific spatial and operational needs of individual laboratories represents a novel and highly compelling approach." "We expect such flexibility will make it possible to implement workflows that deliver high-quality results with minimal reliance on standardized laboratory configurations and staffing resources." "The enthusiastic global response to our concept video and vision for CURECA TM demonstrate the strong demand for next-generation diagnostic solutions," said Jong-Yoon Chun, CEO of Seegene. "We believe CURECA TM has the potential to catalyze meaningful change in the global PCR diagnostics landscape." Please Note: The comments included in this press release are based on actual interviews and on-site discussions. However, in accordance with requests to protect the privacy of the individuals interviewed, all names have been pseudonimized. About Seegene Seegene has more than 20 years of dedicated experience in R&D, manufacturing, and business related to syndromic real-time PCR technologies. This expertise was particularly highlighted during the COVID-19 pandemic when Seegene provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene's syndromic real-time PCR technology is the ability to simultaneously test for 14 pathogens that cause similar signs and symptoms in a single tube with quantitative information. Technology-sharing Initiative The technology-sharing initiative aims to globally share Seegene's advanced diagnostic and data analysis technologies, including syndromic real-time PCR and an automated product development system (SGDDS), with a leading company partnered in each country. Partnering companies will collaborate with local scientists and experts to develop diagnostic tests tailored to the needs of their communities and fields, spanning a wide range of human and non-human diseases. The initiative's ultimate vision is to create "a world free from diseases"—a future where people no longer suffer from infectious diseases and cancer, and where animals and plants thrive without illness.
Cision Canada
02-05-2025
- Business
- Cision Canada
Seegene's CURECA(TM) Emerges as a Potential Game Changer in End-to-End PCR Automation
Seegene previews a concept video of CURECA TM at ESCMID Global 2025, ahead of its anticipated debut in July With a fully modular design, CURECA TM introduces a bold vision for automating pre-treatment across diverse PCR specimen types Developed for future integration into unattended workflows and adaptable laboratory settings SEOUL, South Korea, May 2, 2025 /CNW/ -- Seegene Inc., a global leader in molecular diagnostics (MDx) solutions, has attracted strong interest after the company presented a conceptual video of its CURECA TM at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) in Vienna, Austria. Industry professionals recognized CURECA TM as a promising advancement in automating the entire PCR diagnostic workflow — from primary sample handling to result analysis. In response to the interest received, Seegene provided additional opportunities to showcase the solution at the ESCMID Global 2025. More than 2,300 attendees — including dignitaries from Italy, Spain, Germany, France, and Canada — visited Seegene's booth to view the conceptual video introducing the CURECA TM. "It was evident that the Seegene booth attracted considerable attention at ESCMID," said one professional from academia. Experts Recognize CURECA TM as a Game Changer in Molecular Testing Automation The CURECA TM is designed to automate the entire PCR diagnostic process. It can handle various specimen types required in the pre-treatment stage in MDx – such as stool, urine, blood, and sputum—as well as perform the complete PCR testing workflow following sample loading. The following are select comments from industry professionals who previewed Seegene's CURECA TM at ESCMID Global 2025: "I hold high expectations for the fully automated PCR molecular diagnostics, as CURECA TM not only eliminates human error inherent in manual processes but also enables efficient testing without time or workforce constraints." "We often encounter specimen types that require careful and time-consuming manual pre-processing. A system that can automate this step could represent a true paradigm shift. This level of automation is transformative – a real game changer – and unlike any existing solution. I eagerly await its launch." "If paired with our in-house diagnostic tool kits, CURECA TM could offer a complete synergy. I hope CURECA TM will be accessible to small and mid-sized facilities." "I'm planning to attend ADLM 2025 in Chicago in July to see the actual device and explore potential collaborations." Customizable Pre-Treatment System Offers Versatility for Future Laboratory Automation The first component of CURECA TM is the Customizable Pre-treatment System (CPS). The CPS is designed to automate the loading of primary sample tubes and operate pre-treatment processing. "The CPS is a modular, automated system intended to streamline pre-treatment processing across diverse diagnostic fields including molecular diagnostics such as PCR, as well as clinical chemistry and immunology assays," said Young-Seag Baeg, Head of Strategy and Planning at Seegene. Numerous healthcare (or laboratory) professionals at ESCMID Global 2025 noted that the conceptual video of CURECA TM showcased the potential of fully automated diagnostic laboratories capable of managing complex workflows associated with pre-treatment. In particular, there was consensus among participants that the CPS, which automates specimen preprocessing, is positioned to bring a significant advancement in in vitro diagnostics as it addresses limitations associated with existing manual procedures that are dependent on trained laboratory professionals. "The turnaround time (TAT) is expected to improve with CURECA TM as the integrated software is capable of adjusting workflows based on reporting deadlines," said a director of a laboratory in Spain. "In particular, for sexually transmitted infections (STIs), the CPS will markedly enhance daily laboratory operations. The processing of specimens for STIs involves manual handling of multiple sample tubes, which contributes to operator fatigue. The adoption of the CPS has the potential to be transformational in streamlining routine operations." Modular and Configurable Solution Design for Tailored Diagnostics Following specimen preprocessing, molecular diagnostics typically involve nucleic acid extraction, PCR setup and amplification, and analysis of results. For specimens that do not need preprocessing, Seegene offers the Primary Sample Aliquot System (PAS) as an alternative to the CPS. PAS is designed to allow direct loading and dispensing of primary samples, helping to simplify the workflow. Seegene is pursuing the integration of PAS with a fully automated PCR process through a modular solution concept called CEFA (Customizable & Expandable Full Automation), intended to support diverse laboratory needs with greater flexibility. Seegene aims to leverage the modular architecture of CURECA TM to support a wide range of diagnostic applications. "CURECA TM can be deployed as a comprehensive system or as individual modules—CPS, PAS, and CEFA—configured independently or in combination to accommodate diverse operational needs," said Baeg. Optimizing Lab Workflows Through Space-Saving Design Another key advantage of the CURECA TM 's modular architecture is that it is designed to adapt to different laboratory spaces and layouts. Its flexible design is intended to allow labs to configure the system according to their specific needs, which Seegene sees as essential for enhancing operational efficiency. Laboratory professionals at ESCMID 2025 shared the following perspectives: "The ability to configure a system to meet specific spatial and operational needs of individual laboratories represents a novel and highly compelling approach." "We expect such flexibility will make it possible to implement workflows that deliver high-quality results with minimal reliance on standardized laboratory configurations and staffing resources." "The enthusiastic global response to our concept video and vision for CURECA TM demonstrate the strong demand for next-generation diagnostic solutions," said Jong-Yoon Chun, CEO of Seegene. "We believe CURECA TM has the potential to catalyze meaningful change in the global PCR diagnostics landscape." Please Note: The comments included in this press release are based on actual interviews and on-site discussions. However, in accordance with requests to protect the privacy of the individuals interviewed, all names have been pseudonimized. About Seegene Seegene has more than 20 years of dedicated experience in R&D, manufacturing, and business related to syndromic real-time PCR technologies. This expertise was particularly highlighted during the COVID-19 pandemic when Seegene provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene's syndromic real-time PCR technology is the ability to simultaneously test for 14 pathogens that cause similar signs and symptoms in a single tube with quantitative information. Technology-sharing Initiative The technology-sharing initiative aims to globally share Seegene's advanced diagnostic and data analysis technologies, including syndromic real-time PCR and an automated product development system (SGDDS), with a leading company partnered in each country. Partnering companies will collaborate with local scientists and experts to develop diagnostic tests tailored to the needs of their communities and fields, spanning a wide range of human and non-human diseases. The initiative's ultimate vision is to create "a world free from diseases"—a future where people no longer suffer from infectious diseases and cancer, and where animals and plants thrive without illness. SOURCE Seegene Inc.
